Skip to main content
GNTA logo

GNTA · Genenta Science S.p.A.

$1.30 -0.27 (-17.20%) At close · Jul 29
Market Cap
$75.70M
Shares
48.22M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.30 Open$1.58 Day$1.30–1.60 52W$0.56–10.00 Avg vol 30d170K Short int146K · 0.3% float · 1.5d Short vol1% DataDec 2021–Jul 2026

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 20.7 · elevated Equity put/call 0.61
Technical
price trend
Sell
50 / 200-day cross Golden cross
Price vs 200-day avg −10%
below
Price vs 50-day avg −15%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 8%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −29%
trailing
6-month return +49%
trailing
YTD return −13%
this year
Relative strength +43%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Golden cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow Distributing
3 of 11 funds reported for Jun 30 · net -4.4K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.30% of float · ▼ -12.3% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
11 holders — mid 3-yr range
Squeeze score 32
low risk · 0–100
Fundamentals
Excellent
EPS growth +33%
Y/Y
Balance sheet $25.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 162%
annualized · 1-yr
Max drawdown −91%
past year
ATR 12.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
−10% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
8% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) Golden cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow Distributing
3 of 11 funds reported for Jun 30 · net -4.4K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.30% of float · ▼ -12.3% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
11 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1 Now $1 · 8% 52-wk high $10
vs 200-day avg -10% vs 50-day avg -15% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GNTA
Genenta Science S.p.A.
this stock
$75.70M -12.8% 0.3%
ONC
BeOne Medicines Ltd.
$472.90B +7.7% +22179.2% 962.4 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$122.67B +6.6% +46.2% 28.7 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
$72.91B -9.8% +20.8% 17.0 3.3%
ARGX
Argenx SE
$54.57B +4.9% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
11
% held
2.1%
Reported
3 of 11
Top holder
Eurizon Capital SGR S.p.A.
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
146.0K
Days to cover
1.5d
Change
-20.4K sh
View
Short Volume
Short vol %
1%
As of
Jul 29, 2026
Short Total
View
Fails to Deliver
FTD shares
6.0K
Value
$11.1K
As of
Jun 24, 2026
View
Off-Exchange
Off-exchange %
44.0%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
EUR -6.5M
EPS diluted
EUR -0.33
View
Filings
SEC Filings
Latest
6-K
Filed
Jul 14, 2026
This year
16
View

Performance

5D 20D 120D MTD YTD
GNTA -20.7% -29.4% +48.9% -29.4% -12.8%
SPY -2.4% -2.3% +6.3% -2.3% +7.0%
vs SPY -18.3% -27.0% +42.6% -27.0% -19.7%
Key facts CIK 1838716 CUSIP 36870W100 13F (30d) 3 filings 3 filers Visit website Investor relations